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Abstract
The regulation of phosphate metabolism as an influence on bone homeostasis is profound. Recent 
advances in understanding the systemic control of Fibroblast growth factor-23 (FGF23) has 
uncovered novel effectors of endocrine feedback loops for calcium, phosphate, and vitamin D 
balance that interact with ‘traditional’ feedback loops for mineral metabolism. Not only are these 
findings re-shaping research studying phosphate handling and skeletal interactions, they have 
provided new therapeutic interventions. Emerging data support that the control of FGF23 
production in bone and its circulating concentrations is a multi-layered process, with some 
influences affecting FGF23 transcription and some post-translational modification of the secreted, 
bioactive protein. Additionally, the actions of FGF23 on its target tissues via its co-receptor 
αKlotho, are subject to regulatory events just coming to light. The recent findings of systemic 
influences on circulating FGF23 and the downstream manifestations on bone homeostasis will be 
reviewed herein.
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Introduction
Proper phosphate balance is required for normal bone development, growth, and function, 
therefore blood phosphate is maintained within a fairly narrow range. Prolonged 
hypophosphatemia results in rickets in children through delayed endochondral ossification, 
and osteomalacia in children and adults. Hyperphosphatemia causes delayed bone 
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mineralization, as well as precipitation of phosphate/calcium crystals resulting in ectopic 
and vascular calcification, with secondary effects on bone formation through indirect actions 
on calcitropic hormone production and activity. The bone-derived hormone Fibroblast 
growth factor-23 (FGF23) is central to the maintenance of phosphate balance through its 
actions on its target organs including the kidney and parathyroid gland. The study of genetic 
and acquired diseases involving increased or decreased FGF23 bioactivity have revealed 
novel mechanisms controlling phosphate handling. FGF23 acts through its co-receptor 
αKlotho (αKL), to control renal phosphate and vitamin D metabolism in kidney, the primary 
organ regulating shorter-term blood phosphate concentrations. This review will focus 
primarily upon recent findings describing novel regulators of phosphate metabolism and 
FGF23 that interact with ‘traditional’ endocrine feedback loops, and their downstream 
influences on bone homeostasis. Finally, emerging therapeutic approaches targeting FGF23 
that impact skeletal repair will be discussed.
FGF23 actions in renal mineral metabolism
Systemic phosphate control is critical for hydroxyapatite formation during bone 
mineralization, and is the product of sensitive endocrine feedback loops involving the 
intestine, kidney, and the skeleton. FGF23 is produced in bone following an increase in 
serum phosphate or 1,25(OH)2 vitamin D (1,25D) (1, 2), and acts upon the kidney to 
decrease phosphate (Pi) reabsorption (3). The type-II sodium phosphate co-transporters 
NPT2a and NPT2c are localized to the apical membrane of the renal proximal tubule and are 
the primary regulators of this process. Following FGF23 delivery, these transporters are 
down-regulated fairly rapidly (within one hour) through internalization (3, 4). FGF23 also 
has potent effects on renal 1,25D production and therefore calcium-phosphate balance, as 
FGF23 down-regulates the renal 1α-hydroxylase (Cyp27b1) and stimulates the catabolic 
vitamin D 24-hydroxylase (Cyp24a1), inhibiting the synthesis of active 1,25D (2, 3). 
Therefore, an increase in bioactive FGF23 (‘intact’ or ‘iFGF23’) results in reduced serum 
phosphate with ‘inappropriately’ low or normal plasma 1,25D concentrations, with the 
converse biochemical profile for situations of reduced circulating FGF23. Reduced serum 
phosphate and 1,25D complete the feedback loop by inhibiting FGF23 production in bone 
(Figure 1).
Through genetic and molecular experiments, it was demonstrated that FGF23 requires the 
co-receptor αKlotho (αKL) to elicit high-affinity bioactivity in its target tissues, primarily 
kidney and parathyroid gland (5). The mature αKL protein is produced as several isoforms: 
the ‘membrane’ bound (‘mKL’) form is a 130 kD single-pass transmembrane protein with a 
large extracellular domain that interacts with FGF23, as well as a short intracellular region 
that does not appear to be capable of independent signaling (6). At the cell surface, the 
cleavage of mKL occurs near the transmembrane domain by membrane-bound secretases 
including those from the ADAM and BACE families (7), thereby releasing a circulating 
form of αKL referred to as ‘cut‘ or ‘cleaved-KL’ (‘cKL’). In vitro, mKL recruitment of 
canonical FGF receptors (FGFRs) forms a complex permitting FGF23 signaling (8). Initial 
findings supported specific interactions among FGF23, FGFR1c and αKL (5), however 
multiple ‘c’ isoforms of FGFRs (inclusion of exon 9 vs exon 8 near the transmembrane 
domain) appear to mediate FGF23-αKL signaling in vitro (17). Consistent with FGFR 
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signaling, renal FGF23 bioactivity is primarily mediated through mitogen activated protein 
kinase (MAPK) cascades (9), however whether a single or multiple FGFRs permit FGF23-
αKL signaling in vivo, and the cell-specificity of these interactions, is currently unclear.
To begin to identify the FGFRs involved in FGF23 activity, a study demonstrated that 
individual deletion of FGFR3 and -4 on the Hyp genetic background (mouse model of X-
linked hypophosphatemia (XLH) with 10-fold elevated FGF23) did not correct the 
hypophosphatemia in this model. However, compound deletion of FGFR3/4 partially 
reversed the Hyp biochemical defects (10). In a more recent study, breeding a kidney 
conditional FGFR1-KO using the metanephric mesenchyme Pax3-cre recombinase (global 
FGFR1-KO is lethal) on a global FGFR4-KO background produced double mutant mice 
with significantly elevated serum FGF23 (approximately 45-fold) (11). The compound 
mutants also had elevated serum phosphate despite the high serum FGF23, as well as 
increased brush border membrane phosphate transport (11) and decreased pERK1/2 activity 
in response to FGF23 injections, supporting FGF23 resistance with FGFR deletion. These 
studies were consistent with FGFR1, and perhaps FGFR4, as playing key roles in renal 
FGF23 bioactivity.
To examine the role of FGFR-dependent signaling in renal phosphate metabolism, WT and 
NPT2a-KO mice were provided high and low phosphate-containing feed, as well as acute 
switches between the two diets. Interestingly, during a switch from high phosphate diet to 
low phosphate, over an 8 h time course serum FGF23 concentrations remained steady, 
however brush border membrane Pi transport activity and NPT2a, but not NPT2c and Pit-2, 
abundance acutely increased with this change (12). The adapter protein FRS2α was 
downregulated with diet switch (12), supporting the idea that changes in the expression of 
signaling proteins may control FGF23 bioactivity through FGFRs and αKL in kidney, 
providing a ‘brake’ when FGF23 is inappropriately elevated or during metabolic adaptation.
Local FGFR/FGF regulation of phosphate metabolism through FGF23
Fibroblast growth factor receptor-1 (FGFR1) activity
It has come to light that FGF23 production in bone relies not only upon systemic signals, but 
perhaps more local signals known to be important for bone cell growth and homeostasis, 
including those elicited from the autocrine/paracrine FGFs. To test the role of bone FGFR1 
activity on FGF23 expression, the receptor was conditionally deleted with the osteocyte-
targeted Dentin matrix protein-1 (DMP1)-cre (13). Additionally, to examine the role of 
FGFR1 in XLH, Hyp mice were generated with osteocyte-deleted FGFR1. Dmp1-cre/
FGFR1−/− mice had significantly reduced serum intact FGF23 concentrations versus the 
prevailing elevated levels in Hyp mice, but no alterations in serum phosphate, vitamin D 
homeostasis, or discernable effects on the skeleton. Interestingly, compound Hyp/FGFR1−/− 
mice had improvement of the ricketic and osteomalacia phenotypes as well as a significant 
reduction in serum FGF23 and increased serum phosphate compared to Hyp (13). These 
results were corroborated in vitro with the demonstration that FGF23 promoter activity 
could be stimulated with FGFR1 agonists and was inhibited by a dominant negative FGFR1 
construct as well as PLC and MAPK inhibitors. In addition, delivery of a monoclonal anti-
FGFR1 activating antibody ‘R1Mab’ to normal mice resulted in increased FGF23 and a mild 
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hypophosphatemia (14), and treatment of primary cultures of differentiated rat osteoblasts 
induced FGF23 mRNA and FGF23 secretion. Interestingly, treatment of a kidney cell line 
with R1Mab was FGF23-mimetic and FGFR1 knockdown experiments inhibited these 
effects (14). Thus, bone and kidney FGFR1 expression may be required for maintaining 
normal circulating concentrations of FGF23.
FGF2 isoforms
Studies have also tested the cognate ligands for FGFR-mediated regulation of FGF23 
production in bone. Low molecular weight (18 kD) FGF2 activates cell surface FGFRs, but 
high molecular weight (HMW)-FGF2 isoforms interact with intranuclear FGFR1 to activate 
integrative nuclear FGFR1 signaling (INFS). Interestingly, over expression of nuclear 
HMW-FGF2 in bone increased FGF23 production and induced a hypophosphatemic rickets 
phenotype (15). Bone marrow stromal cell cultures (BMSCs) from HMW-FGF2 transgenic 
mice had elevated FGF23, and an intrinsic defect in mineralization which was rescued by an 
FGF23 neutralizing antibody, a MAPK inhibitor and an FGFR tyrosine kinase inhibitor (15). 
Conversely, global deletion of HMW-FGF2 resulted in mice with high BMD versus control 
littermates with increased osteoblastic activity (16). Although there was a reduction of 
FGF23 mRNA in the HMWFGF2-KO mice, normal serum phosphate and PTH were 
observed (16). Taken together, these studies suggest that HMW-FGF2 may influence bone 
through controlling FGF23 production (Figure 1), and in situations of very high levels, 
FGF23 may act on bone cells through FGFRs. The extent of the role of HMW-FGF2, and 
whether control of this factor affects FGF23 in disorders of phosphate handling remain to be 
determined.
To identify the functional differences between FGF2 isoforms (HMW and low molecular 
weight or ‘LMW’), studies were also undertaken in isolated osteoblast cell lines. It was 
shown that LMW-FGF2 induced NFAT and Ets1 binding and activation of the FGF23 
promoter through the PLCγ/calcineurin/NFAT and MAPK pathways (17). In contrast, 
HMWFGF2 demonstrated cAMP-dependent binding of FGFR1 and cAMP-response 
element-binding protein (CREB) to a conserved cAMP response element (CRE) in the 
FGF23 promoter adjacent to the NFAT binding site (17). These findings are consistent with 
the above studies in which deletion of FGFR1 in normal and Hyp osteocytes reduced 
FGF23, and implicate FGF2 as a possible FGFR1 ligand playing a role in normal FGF23 
expression.
Circulating αKlotho and interactions with bone
The role of skeletal FGFRs in the control of FGF23 may also be associated with systemic 
regulators of phosphate homeostasis including cKL. A patient with severe 
hypophosphatemia and harboring a balanced chromosomal translocation (t9:13) in proximity 
to the αKLOTHO gene was identified (18). In addition, this patient had elevated FGF23, 
inappropriately normal 1,25D, as well as hyperparathyroidism. Upon testing the patient’s 
serum it was determined that the translocation caused elevated cKL(18), supporting that the 
excess cKL drove the expression of FGF23 under prevailing hypophosphatemic conditions 
(Figure 1), typically suppressive for FGF23 production. In an effort to determine the 
molecular mechanisms underlying the role of cKL in FGF23 expression, using adeno-
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associated virus (AAV-cKL) this isoform was delivered to mice for 4–8 weeks (19). Similar 
to the translocation patient, the cKL-treated mice had highly elevated serum intact FGF23 
with osteomalacia, as well as increased bone FGF23 mRNA despite hypophosphatemia. In 
vitro, treatment of FGFR1-stably expressing cells with cKL resulted in increased p-ERK1/2 
activity, supporting interactions between cKL and FGFRs upstream of FGF23 production 
(19). The regulation of cKL cleavage from mKL in terms of phosphate handling is not well 
understood, however the major site of αKL expression is kidney, thus molecular interactions 
between cKL and FGFRs in bone could potentially act to fine-tune circulating FGF23.
PTH, calcium balance and FGF23 interactions
In addition to local control of FGF23 in bone, key findings in the systemic regulation of 
FGF23 have revealed potentially novel regulatory steps in phosphate homeostasis. PTH is 
secreted following a reduction in serum Ca2+ concentrations, and acts upon the renal distal 
nephron to increase Ca2+ reabsorption, as well as down-regulates NPT2a in proximal tubule 
cells to reduce phosphate reabsorption (20). PTH also increases the renal 1α-hydroxylase 
(Cyp27b1), thus stimulating the synthesis of active 1,25D, the reciprocal effect of FGF23. 
The elevation in plasma 1,25D promotes calcium and phosphate absorption in the intestine, 
and through negative feedback reduces PTH production in the parathyroid glands (Figure 1). 
The relationships between PTH and FGF23 in vivo appears to be more complex than those 
between 1,25D and FGF23, where 1,25D has been shown to directly stimulate FGF23 
production through VDR sites on the FGF23 promoter in vitro (21), supporting in vivo 
studies with similar effects on FGF23 following 1,25D injections into rodents (2). Results 
from ex vivo studies demonstrated that FGF23 suppressed PTH in cultured bovine 
parathyroid cells (22) and during direct incubation of the exposed parathyroid gland in live 
rats (23). The parathyroid glands are known to express αKL (22, 23), and the inhibition of 
PTH by FGF23 is in agreement with a potential negative feedback loop where PTH 
increased FGF23 in primary cultures of differentiated osteoblasts/osteocytes (24).
To identify the mechanisms underlying the influence of FGF23 on PTH, conditional genetic 
studies have been performed in mice. In this regard, parathyroid-specific deletion of αKL 
with a PTH-promoter Cre (producing PTH-KL−/− mice) reduced MAPK/ERK signaling 
(25), thought to be the primary pathway for FGF23-αKL-FGFR bioactivity (26). In mice 
devoid of parathyroid αKL, PTHR expression, serum PTH concentrations, as well as 
responses to FGF23 challenge were not different from control mice however (25). In 
contrast, serum 1,25D concentrations in PTH-KL−/− mice were double those of control 
littermates. The nuclear factor of activated T-cells (NFAT) cascade was then tested as an 
alternative FGFR-mediated signaling pathway in parathyroid glands (25). Interestingly, the 
PTH-KL−/− mice had constitutively active calcineurin-NFAT signaling, as tested by 
increased MCIP1 and nuclear localization of NFATC2. Treatment of the PTH-KL−/− mice 
with the calcineurin-inhibitor cyclosporine A abolished FGF23-mediated PTH suppression 
whereas wild type mice remained responsive to FGF23 administration. Similar results were 
observed in thyro-parathyroid explants, supporting FGF23 actions through an FGFR and 
NFAT signaling (25), however the FGFR receptor(s) guiding these pathways have yet to be 
identified. Taken together, these studies support the concept that FGF23 may signal through 
mechanisms in addition to αKL-FGFR MAPK/ERK cascades in the parathyroid glands. 
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Additionally, future studies on patients receiving kidney transplants and treated with 
immunosuppressive therapies, such as cyclosporine A, could be an important research area 
as this patient population may be susceptible to enhanced PTH secretion.
To test the mechanisms underlying the effects of PTH-stimulated FGF23 expression in bone 
as the closing actions in a negative feedback loop between the parathyroids and bone, the 
nuclear orphan receptor Nurr1 was examined as downstream of PTH actions (27). Results 
using the UMR-106 osteosarcoma cell line demonstrated that Nurr1 was required for the 
FGF23 mRNA increases following PTH treatment. In addition, luciferase and ChIP assays 
supported direct interactions between Nurr1 and the FGF23 promoter (27). In a rat CKD 
model the calcimimetic R586 decreased Nurr1 expression which coincided with decreases in 
FGF23 mRNA. Thus, the presence of a feedback loop between bone and parathyroid 
through FGF23 may be important for maintaining skeletal homeostasis through phosphate 
and calcium balance.
Calcium and FGF23
FGF23 activity in the kidney can affect not only phosphate handling, but calcium 
metabolism through its actions on 1,25D and PTH production. However, whether calcium 
plays a direct role in FGF23 induction within a novel feedback loop is unclear. Indeed, when 
FGF23 suppresses renal 1,25D production, dietary uptake of phosphate and calcium is 
reduced. PTH, as stated above, counters the FGF23 effects on kidney 1,25D production, 
therefore it was postulated that excess calcium stimulates FGF23 in a feedback regulatory 
loop similar to phosphate. Treating mice for 4 weeks with PTH, 1,25D or placing mice on a 
high calcium (2%)/high phosphate (1.2%) diet for 9 weeks showed a significant positive 
correlation between serum calcium and iFGF23 although FGF23 is known to be stimulated 
by PTH, 1,25D and high phosphate (28). Increased blood calcium represses serum PTH 
within 5 minutes after infusion (29). In contrast, response of FGF23 was delayed with a 
modest induction of serum intact levels at 5 hours after calcium injection, and continued in 
an upward trend to 12 hours post treatment (28). Genetic ablation of PTH or the calcium 
sensing receptor (CaSR) in vivo did not prevent calcium from stimulating FGF23 protein 
(30). Conversely, Cyp27b1-KO mice which are hypophosphatemic due to a lack of 1,25D 
production, showed no increase in FGF23 when give a bolus injection of calcium (28, 31). 
This suggests, in parallel to other in vivo studies, low phosphate levels may block the ability 
of calcium to activate FGF23 (Figure 1). In corollary in vitro studies, addition of exogenous 
calcium modestly increased FGF23 promoter activity and treatment of cells with the calcium 
channel blocker nefidipine ablated the promoter response to calcium. Additionally, in 
concordance with in vivo studies, cells cultured in low calcium conditions elicited no 
upregulation of FGF23 in the presence of known activators 1,25D or phosphate (28, 31). 
Although the molecular mechanisms behind this regulation remains unknown, direct 
interactions of calcium and phosphate at the bone cell level may be instrumental for the 
regulation of FGF23.
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Dynamic post-translational processing of FGF23 and systemic impact
Circulating FGF23 increases in response to a positive phosphate balance in mice and 
humans (32, 33), but to date a phosphate-sensor system that controls FGF23 production in 
bone (or through indirect actions of other tissues) has not been identified. In addition to 
effects on FGF23 mRNA levels, recent evidence suggests that the control of iFGF23 
secretion may arise through post-translational regulation via a process involving step-wise 
modifications and minute to minute ‘decision-making’ on the status of FGF23 protein by 
osteoblasts and osteocytes. This cell system has activity that results in either iFGF23 
secretion (residues 25-251 comprises the full-length protein), or secretion as at least two 
inactive proteolytic cleavage products: (N-terminal residues 25-179) and C-terminal residues 
180-251). There are several ELISAs available to measure serum FGF23. ELISAs that 
recognize FGF23 antigens ‘C-terminal’ (‘cFGF23’) to the FGF23 176RXXR179/S180 SPC 
cleavage site (from Immutopics, Int’l.; (34)) have been developed for human and rodent 
FGF23. This assay binds bioactive iFGF23, as well as C-terminal proteolytic fragments that 
arise from cleavage of the mature hormone. The cFGF23 assays therefore may act as an 
approximate serum ‘read out’ for bone FGF23 mRNA concentrations. An ELISA that uses 
conformation-specific monoclonal antibodies that biochemically react with epitopes N- and 
C-terminal to the FGF23 176RXXR179/S180 SPC site detects iFGF23 across a fairly wide 
species range (from Kainos, Inc.; (35)). More recently, a rodent-specific iFGF23 assay has 
been developed that reacts with rat and mouse FGF23 but not human (from Immutopics, 
Int’l.). As described below, the assays have been useful in determining the ratios of 
iFGF23:cFGF23, which are diagnostic for changes in the balance of circulating FGF23 
isoforms under systemic challenge, and in some FGF23-related diseases where patients have 
inappropriate ‘over’ or ‘under’ degradation of FGF23 protein.
Mature FGF23 protein is O-glycosylated on T178 by the GALNT3 GalNAc-transferase 
within the FGF23 RHT178R/S subtilisin-like proprotein convertase protease (SPC) motif, 
and this glycosylation is necessary for intact hormone stability (36, 37). Clues to the concept 
of regulated FGF23 protein processing to control active blood levels arose from the disorder 
GALNT3-hfTC (hyperphosphatemic familial tumoral calcinosis) and the hfTC variant 
hyperostosis-hyperphosphatemia syndrome (HHS). In these conditions, loss of function 
mutations in GALNT3 lead to destabilization of iFGF23 from lack of glycosylation and thus 
‘protection’ of the RHTR/S cleavage site. The excess FGF23 proteolysis results in the 
ELISA detection of low iFGF23 but high cFGF23 in patient sera (38). To test the molecular 
relationships between GALNT3 and FGF23, the GALNT3-KO mouse was bred with the 
autosomal dominant hypophosphatemic rickets (ADHR) knock-in mouse, which carries an 
orthologous human FGF23 stabilizing mutation (R176Q) (39). Biochemical phenotyping of 
the GALNT3-KO/ADHR mice demonstrated that the ADHR mutation completely rescued 
the serum phosphate and elevated cFGF23 (an indicator of ‘over-cutting’ and inactivation of 
FGF23) in the GALNT3-KO mice (40), supporting the importance of the SPC motif in 
FGF23 stabilization and therefore activity. Additionally, recent results from the Mendelian 
disorder Raine’s syndrome (ARHR Type 3), a recessive disorder that results from loss of 
function mutations in the Family with sequence similarity 20, member C (FAM20c) pointed 
to FGF23 stabilizing events reciprocal to degradation in hfTC (41). FAM20c is an ‘atypical’ 
Clinkenbeard and White Page 7
Curr Mol Biol Rep. Author manuscript; available in PMC 2017 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
kinase localized to the trans-Golgi network (TGN) that phosphorylates proteins within 
multiple motifs (42, 43), including Serine-x-Aspartic acid (‘S-x-E’) residues, which are 
found on secreted extracellular matrix proteins such as osteopontin (OPN) and DMP1 (43, 
44). Interestingly, in a patient with Raine’s syndrome, compound heterozygous mutations in 
FAM20c were associated with increased plasma iFGF23 (45). This patient was 
hypophosphatemic in childhood, had marked dental disease from infancy, as well as the 
formation of ectopic brain calcifications. Similar to Raine’s patients, Fam20c-KO mice also 
have increased iFGF23 and severe hypophosphatemia (46).
It was noted that the C-terminal portion of the FGF23 SPC protease site contains an S-x–E 
motif: 176RHT178R179/S180AE. Subsequently, mass spectrometry revealed that FAM20c 
phosphorylated FGF23 on S180 (47), and in vitro studies demonstrated that this 
phosphorylation event prohibits GALNT3 O-glycosylation of T178, making FGF23 
susceptible to intracellular protease cleavage (47). Wild type FAM20c almost completely 
blocked FGF23 glycosylation, whereas co-expressing FAM20c cDNA carrying a Raine’s 
syndrome mutation only partially inhibited GALNT3 glycosylation of FGF23. This 
observation supports that patients with Raine syndrome and elevated FGF23 likely have 
reduced ability to phosphorylate FGF23 S180, enhancing GALNT3 glycosylation on T178 
and thus leading to a greater proportion of iFGF23 and the hypophosphatemic phenotype 
(47). The SPC protease that catalyzes the cleavage of FGF23 was uncertain, but of the 
isoforms tested, PSCK1-3 (furin) was capable of cleaving native (un-phosphorylated) or 
FGF23 phosphorylated at S180, consistent with the idea that furin could be another key target 
for modifying the balance of circulating concentrations of iFGF23 and cFGF23 (Figure 1). 
Solving the crystal structure for FAM20c demonstrated that there are no classic kinase 
activation loop domains (48) indicating that the cellular secretion of FAM20c could be the 
primary mode to reduce activity, consistent with the ability to sense minute to minute 
changes in serum phosphate or respond to hormonal stimuli. Additionally, inactivating 
mutations in a related gene, FAM20a, cause amelogenesis imperfecta and gingival 
fibromatosis syndrome (49), and mouse deletion of FAM20a is associated with severe 
enamel anomalies (50). FAM20a was determined to be a pseudokinase that forms a 
functional complex with FAM20c, giving FAM20c higher activity (51). Thus, modification 
of interactions between FAM20c and −20a could also affect the bioactivity of circulating 
iFGF23 through enabling or preventing FGF23 phosphorylation and ultimately its 
degradation.
Responses to Systemic Iron Metabolism
Emerging data from clinical and translational studies demonstrated that FGF23 is controlled 
in bone by pathways not previously associated with phosphate metabolism. In this regard, 
early clinical studies reported that patients with anemia and treated with specific iron 
preparations (such as iron maltose but not iron dextran) had associated elevations in FGF23, 
as well as hallmark manifestations of excess FGF23 including hypophosphatemia with 
inappropriately normal or reduced 1,25D (52, 53). Maintaining proper iron handling is 
important for bone growth due to deleterious direct and indirect effects of excess iron and 
anemia. Iron metabolism in bone is important for proper collagen synthesis through 
modifications controlling protein hydroxylation (54), as well as renal 1,25D production as an 
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integral portion of the CYP family of metabolic enzymes (55), and iron overload leads to 
oxidative stress in bone and other tissues (56). Additional clues to FGF23 regulation by 
factors outside of the characterized feedback loops known to exist for phosphate metabolism 
came from the close examination of ADHR patients (39). ADHR is a disorder of FGF23 
excess due to FGF23 gain of function mutations occurring within the FGF23 SPC 
proteolytic cleavage site (176RHTR179/S180AE) (39), and substitute the charged arginines 
(R) at positions 176 or 179 with glutamine (Q) or tryptophan (W) (39, 57, 58). Upon 
modification of the SPC recognition motif by the ADHR mutations, an FGF23 species more 
resistant to intracellular furin-like cleavage and inactivation is produced.
The late-onset ADHR disease phenotypes arise in physiological situations of iron deficiency, 
such as puberty and during pregnancy (59). In patients with ADHR, increases in iFGF23 and 
cFGF23 occur in parallel with disease onset as determined using the intact and C-terminal 
ELISAs. It was discovered iFGF23 and cFGF23 were inversely correlated with serum iron 
concentrations in ADHR, but only cFGF23 was elevated coincident with low iron in control 
subjects (60). This may indicate that normal individuals ‘sense’ the amount of FGF23 
required for proper phosphate homeostasis and proactively cleave iFGF23 to maintain 
appropriate circulating concentrations. Additionally, the inverse nature between serum iron 
and iFGF23 was evident for 1,25D and serum phosphate in ADHR patients during 
longitudinal analyses (60), as would be expected if low serum iron increased iFGF23 as the 
‘driver’ of the biochemical manifestations in ADHR. Interestingly, when tested in XLH 
patients, serum cFGF23 and iFGF23 were higher in XLH patients, but similar to normal 
individuals, the ratio of cFGF23 to iron was inversely proportional and there was no 
significant relationships between serum iron and iFGF23 (61). These studies support that the 
pathogenesis of elevated iFGF23 in XLH is different from ADHR and it would be expected 
therefore, that iron repletion therapy would be likely to impact patients with ADHR versus 
those with XLH (see below).
Due to the fact that ADHR is unique among the FGF23-related disorders of phosphate 
handling in that patients display early or late onset, the ADHR knock-in mice were placed 
on an iron-deficient diet to mechanistically test the role of anemia in FGF23 regulation (62). 
After receiving low iron diets, adult ADHR mice increased bone FGF23 mRNA, and similar 
to ADHR patients had elevated serum iFGF23 and cFGF23 with significant 
hypophosphatemia. In contrast, wild type (WT) mice also increased FGF23 mRNA, but had 
normal iFGF23 with elevated cFGF23. Taken together these results suggested that anemia 
stimulated FGF23 transcription, but ADHR mice could not compensate by cleaving FGF23 
due to the proteolytic-resistant R176Q-FGF23. However, WT mice could inactivate FGF23 
through proteolysis, evident by the elevated cFGF23 and normal iFGF23, and accompanying 
normal serum phosphate (62), in parallel to the above clinical ADHR results. To examine 
FGF23 in pregnancy and during neonatal life, in a translational study pregnant WT and 
ADHR breeder mice were placed on low iron diets the final week of pregnancy (days 14–21) 
to mimic iron deficiency anemia in last trimester, and maintained on this diet to nurse pups 
until weaning (3 weeks of age) (63). Both WT and ADHR pups were hypophosphatemic 
with markedly increased iFGF23, with the ADHR mice being more severely affected due to 
the stabilizing R176Q FGF23 mutation. Additionally, hypoxia was tested under cell culture 
conditions and FGF23 mRNA was significantly increased coordinate with stabilization of 
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the iron-sensing transcription factor Hypoxia inducible factor (HIF)-1α (63). 
Hypophosphatemia is also associated with states of inflammation such as sepsis. Recent 
evidence supports that agents associated with inflammation such as TNF and IL-1β stimulate 
FGF23 production in cultured osteocyte cell lines and human bone samples in an NF-κB-
dependent manner (64). Further research is needed in this interesting area, as these studies 
suggest that iron and inflammation could potentially affect circulating FGF23 in vivo, 
however in a study examining children, FGF23 was associated with iron status and not 
inflammation markers (65).
Emerging Treatments
Iron therapy for ADHR
The findings that ADHR patients (60) and ADHR mice (62, 63) had elevated iFGF23 during 
iron deficiency, coupled with the fact that iron supplementation in ADHR mice reversed the 
increased iFGF23 and hypophosphatemia (63), and FGF23 is associated with iron levels in 
children (65) provided the basis for the hypothesis that if anemic, ADHR patients may 
reduce FGF23 and benefit from iron repletion. In a case study, a child with ADHR 
(confirmed FGF23 R179Q mutation) and a family history of waxing and waning of disease 
was provided high dose iron supplementation. This patient was withdrawn from phosphate 
and alfacalcidol (1,25D analog) due to the fact that her father’s symptoms spontaneously 
resolved, however her hypophosphatemia did not improve (66). The patient then received 
increasing doses of iron supplements (iron (II) sulfate), which increased serum iron and in 
parallel, improved serum phosphate and TmP/GFR, and was associated with elevated serum 
1,25D. Over a period of 6 months, serum iron was stabilized and the rickets medication was 
reduced, then withdrawn, and iron supplementation ceased (66). After all medication 
withdrawal iFGF23 was normalized in the patient. Although it cannot be completely ruled 
out that patient’s improvement could be due to factors outside of iron homeostasis given that 
she was followed for almost 9 years and considering the documented waxing and waning of 
ADHR. Although more patients should be observed, the steadily improved patient 
biochemical profile and pronounced effects on 1,25D while receiving iron supplementation 
are consistent with the potential use of iron as a novel stand alone, or combination therapy, 
for clinical management of ADHR.
FGF23 neutralizing antibody
The current therapy for FGF23-mediated hypophosphatemic disorders consists of high dose 
oral calcitriol (1,25D analog) and phosphate, which usually leads to healing of the rickets 
and osteomalacia. However the treatment can have complications including diarrhea from 
phosphate, hyperparathyroidism, and nephrocalcinosis. It was reported that the 
hypophosphatemic rickets phenotype of the Hyp mouse model of XLH could be almost 
completely reversed using FGF23 neutralizing antibodies (67). With the development of 
humanized monoclonal antibodies specifically targeting iFGF23 (‘KRN23’), a single dose 
early phase trial to treat XLH patients was undertaken (68). Injection of the antibody 
subcutaneously resulted in increased TMP/GFR, as well as elevated serum phosphate and 
1,25D concentrations. Hyperphosphatemia was not a complication although plasma 1,25D 
was elevated at higher doses over a time course of up to 50 days. An escalation and extended 
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time course study of KRN23 was then undertaken in a subset of patients with a dosing 
regimen of up to one year (69). During the extended phase of the trial, monthly KRN23 
delivery increased serum phosphate and TmP/GFR in all subjects. Although 1,25D 
concentrations transiently increased, average serum and urinary calcium remained within the 
normal ranges (69). Thus, long term treatment blocking the activity of FGF23 may be a 
novel therapeutic approach for XLH and other FGF23-related diseases, including tumor 
induced osteomalacia (TIO), an acquired hypophosphatemic disease where patients have 
FGF23-producing mesenchymal tumors that are often difficult to localize (70).
Conclusions
In conclusion, recent work has shown that the interplay of systemic factors such as ions, 
including calcium, phosphate, and iron, as well as hormones including PTH and 1,25D, in 
combination with local factors such as FGFs, play essential roles in bone FGF23 production, 
intracellular processing, and function. The downstream actions on bone caused by 
modifying circulating FGF23 impacts important features of bone homeostasis including 
mineralization. Arising from this collective work are several new therapeutic paradigms 
targeting FGF23 and its effectors for treating diseases of altered mineral metabolism.
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Figure 1. Schematic of FGF23 pathways affecting systemic actions of FGF23 and bone 
homeostasis
FGF23 is produced in osteoblasts and osteocytes (left) and controls phosphate (Pi) 
metabolism in the kidney and parathyroid glands, sites of αKL expression (green lines 
indicate stimulatory pathways, red lines inhibitory). In kidney, FGF23 reduces phosphate 
reabsorption through down regulation of NPT2a and NPT2c, and decreases 1,25D 
production through control of 1,25D metabolizing enzymes. The resulting decreases in 
serum phosphate from decreased 1,25D-dependent intestinal Pi absorption reduce FGF23 
production in bone through a negative feedback loop. Evidence supports PTH stimulation of 
FGF23 in bone, and FGF23 acts in the parathyroid glands to reduce PTH. Other regulators 
such as calcium (Ca2+), and iron (Fe3+) deficiency may act directly on osteoblasts/osteocytes 
to increase FGF23 mRNA. The intracellular factors FAM20c, GALNT3, and Furin are 
dynamically controlled to influence the production of either bioactive, intact FGF23 
(iFGF23) or inactive FGF23 fragments as another important mode to regulate iFGF23 
concentrations. Factors such as cKL and FGF2/FGFR1 likely act in bone to control 
circulating FGF23. Iron (II) sulfate therapy and FGF23 neutralizing antibodies reduce 
FGF23 production and bioactivity, respectively.
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